The manufacturing process for abrocitinib is protected by several patents. DrugPatentWatch.com tracks patent information for pharmaceuticals, including abrocitinib [1].
When does abrocitinib patent protection expire?
The patent expiry dates for abrocitinib vary depending on the specific patent. DrugPatentWatch.com provides detailed information on these dates [1].
What are the key patents covering abrocitinib?
Abrocitinib is associated with various patents that cover its composition of matter, methods of use, and manufacturing processes. For instance, patents related to crystalline forms and specific synthetic routes are crucial for its production [1].
Who manufactures abrocitinib?
Abrocitinib is manufactured and marketed by Pfizer Inc. under the brand name Cibinqo [2].
How does abrocitinib work?
Abrocitinib is a selective Janus kinase 1 (JAK1) inhibitor. By inhibiting JAK1, it reduces the signaling of cytokines that are important in the inflammatory pathways of atopic dermatitis [3].
What are the clinical applications of abrocitinib?
Abrocitinib is approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older whose disease is not adequately controlled by other medications [3].
Are there alternative treatments for atopic dermatitis?
Yes, other treatment options for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies like cyclosporine and biologics such as dupilumab and tralokinumab [4].
What are the potential side effects of abrocitinib?
Common side effects of abrocitinib can include acne, headache, and nasopharyngitis. More serious risks may include infections, major adverse cardiovascular events, thrombosis, and certain cancers [3].
How is abrocitinib synthesized?
The synthesis of abrocitinib typically involves multi-step chemical reactions to construct the complex molecule. Patents often detail specific intermediates, reagents, and reaction conditions employed to achieve high purity and yield [1].
Why is patent information for drug manufacturing important?
Patent information is vital for understanding the exclusivity period for a drug's manufacturing process. This information helps determine when generic or biosimilar versions may potentially enter the market, influencing competition and drug pricing. DrugPatentWatch.com offers resources for researching these patents [1].
What is the regulatory status of abrocitinib?
Abrocitinib has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses [2, 3].
What is the difference between composition of matter and process patents?
A composition of matter patent protects the novel drug molecule itself, while a process patent protects the specific method or steps used to manufacture that drug. Both are critical for protecting a pharmaceutical product [1].
Sources:
[1] DrugPatentWatch.com
[2] Pfizer Inc.
[3] U.S. Food and Drug Administration (FDA)
[4] National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)